FMP
Valbiotis SA
ALVAL.PA
EURONEXT
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
1.11 EUR
0.002 (0.18%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Sebastien Peltier HDR, Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.valbiotis.comexchange
EURONEXT
Description
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
CIK
N/A
ISIN
FR0013254851
CUSIP
F966A0104
Address
rue Paul Vatine
Phone
33 5 46 28 62 58
Country
FR
Employee
52
IPO Date
Jun 7, 2017
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ALVAL.PA Financial Summary
CIK
-
Exchange
EURONEXT
Industry
Biotechnology
Sector
Healthcare
CUSIP
F966A0104
ISIN
FR0013254851
Country
FR
Price
1.11
Beta
-0.09
Volume Avg.
88.19k
Market Cap
17.53M
Shares
-
52-Week
0.986-4.73
DCF
-0.16
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.77
P/B
-
Website
https://www.valbiotis.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ALVAL.PA News
It looks like there's no news available.
